Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Withdrawn study sought safer biopsies for Bleeding-Prone patients

NCT ID NCT05790109

Knowledge-focused Sponsor: Brigham and Women's Hospital Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled This study
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 2 times

Summary

This study planned to test a technique called radiofrequency track cautery during liver, kidney, or spleen biopsies in patients at high risk for bleeding. The idea was to use a small heated probe to seal the biopsy track and reduce bleeding. However, the study was withdrawn before enrolling any participants, so no results are available.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
radiofrequency cautery device

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Started

May 2023

Finished

Jun 2023

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: Patients referred to interventional radiology for clinically indicated liver, kidney, or spleen biopsy for diffuse or focal disease, who also have one or more of the following risk factors for bleeding: * Coagulopathy (INR ≥ 1.5) or thrombocytopenia (platelets \< 50) before correction * Renal disease with glomerular filtration rate (GFR) \< 30 ml/min * Liver cirrhosis * Anticoagulant or antiplatelet medications where periprocedural withholding poses * Competing medical risk, or the urgency of the procedure precludes holding the anticoagulant medications for the standard interval (departmental guidelines). * Any splenic biopsy * Hypervascular masses in the liver or kidney * Renal and liver parenchymal biopsies, which are known to carry a higher risk of bleeding. Exclusion Criteria: * Uncorrectable coagulopathy (INR remaining ≥ 2.5) or thrombocytopenia (platelets remaining \< 25) * Pregnancy * Patients who are not competent to provide their own consent

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Bleeding disorder are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Hemorrhage hemorrhagic disease impaired renal function disease kidney disorder liver disorder vascular hemostatic disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Bleeding disorder Kidney diseases Liver diseases Spleen lesion

Contacts and locations

Locations

  • Brigham and Women's Hospital

    Boston, Massachusetts, 02114, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.